Bystander or no bystander for gene directed enzyme prodrug therapy.

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Gabi U DachsA V Patterson

Abstract

Gene directed enzyme prodrug therapy (GDEPT) of cancer aims to improve the selectivity of chemotherapy by gene transfer, thus enabling target cells to convert nontoxic prodrugs to cytotoxic drugs. A zone of cell kill around gene-modified cells due to transfer of toxic metabolites, known as the bystander effect, leads to tumour regression. Here we discuss the implications of either striving for a strong bystander effect to overcome poor gene transfer, or avoiding the bystander effect to reduce potential systemic effects, with the aid of three successful GDEPT systems. This review concentrates on bystander effects and drug development with regard to these enzyme prodrug combinations, namely herpes simplex virus thymidine kinase (HSV-TK) with ganciclovir (GCV), cytosine deaminase (CD) from bacteria or yeast with 5-fluorocytodine (5-FC), and bacterial nitroreductase (NfsB) with 5-(azaridin-1-yl)-2,4-dinitrobenzamide (CB1954), and their respective derivatives.

Citations

Jun 8, 2012·Applied Biochemistry and Biotechnology·Vinod Kumar YataSiddhartha Sankar Ghosh
May 19, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bonan ZhongHans-Peter Kiem
Jan 13, 2011·BMC Biotechnology·Peter M HuelsmannChristian Berens
Aug 16, 2014·Nitric Oxide : Biology and Chemistry·Kavita Sharma, Harinath Chakrapani
Jul 6, 2014·Protein Engineering, Design & Selection : PEDS·J N CoppD F Ackerley
Apr 9, 2013·Pharmacological Reports : PR·Jolanta B ZawilskaAgnieszka B Olejniczak
Mar 19, 2016·Cancer Medicine·Günther BonifertOliver Spadiut
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Zheng LvDe-Shan Li
May 26, 2015·Advanced Drug Delivery Reviews·Zahra KarjooArash Hatefi
Mar 15, 2013·Cancer Letters·Lucia KucerovaMartina Poturnajova
Oct 24, 2014·The AAPS Journal·Jin ZhangMingnan Chen
Jul 28, 2016·Biochemical Pharmacology·Alexandra M MowdayAdam V Patterson
Dec 21, 2011·Cancer Letters·Edouard I AzzamDebkumar Pain
Mar 28, 2018·International Journal of Molecular Sciences·Senthilkumar KalimuthuByeong-Cheol Ahn
Sep 2, 2018·The Journal of Gene Medicine·Nejat DüzgüneşKrystyna Konopka
Mar 27, 2019·Therapeutic Delivery·Steen J Madsen, Henry Hirschberg
Dec 7, 2018·The Open Medicinal Chemistry Journal·Abhinav P MishraGaurav Tiwari
Oct 4, 2015·The Biochemical Journal·Elsie M WilliamsDavid F Ackerley
Feb 17, 2019·International Journal of Molecular Sciences·Chizuru IwasawaHiroyuki Miyoshi
Feb 14, 2021·Cancers·Kerry FisherLeonard W Seymour
Feb 20, 2020·Molecular Therapy. Methods & Clinical Development·Graça Almeida-PoradaChristopher D Porada

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
surgical resection
biopsy
deamination
PCR
xenografts

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.